Novavax teases Covid-19 vaccine trial design as it kicks off UK study — US to follow next month
Ahead of a US trial set to begin in October, Novavax has begun the first Phase III study for its Covid-19 vaccine candidate in the UK.
Add a smaller safety trial planned in South Africa, and you have three late-stage shots on goal for the Maryland-based biotech, which (like frontrunner Moderna) has never brought a vaccine to the market. But that didn’t stop Operation Warp Speed from betting $1.6 billion on its recombinant protein nanoparticle approach.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
